Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
NCT ID: NCT00062023
Last Updated: 2012-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
12 participants
INTERVENTIONAL
2003-06-30
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase II trial is studying how well sulindac works compared to aspirin or ursodiol in preventing colorectal cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the percentage change in colorectal aberrant crypt foci (ACF) in patients with a history of colorectal cancer or at high risk for colorectal cancer when treated with sulindac vs aspirin vs ursodiol.
* Determine the safety and efficacy of these drugs, in terms of ability to cause regression of existing colorectal ACF and prevent new ACF development, in these patients.
OUTLINE: This is a partially blinded, randomized, placebo-controlled study. Patients are stratified according to colorectal neoplasia (adenoma vs carcinoma). Patients are randomized to 1 of 4 treatment arms.
* Arm I: Patients receive oral sulindac twice daily.
* Arm II: Patients receive oral aspirin once daily.
* Arm III: Patients receive oral ursodiol three times daily.
* Arm IV: Patients receive oral sulindac placebo twice daily. In all arms, treatment continues for 12 months in the absence of disease progression or unacceptable toxicity.
Patients undergo a colonoscopy at baseline and at the end of treatment.
Patients are followed at 2 months after the end of treatment.
PROJECTED ACCRUAL: A total of 172 patients (43 per treatment arm) with a history of colorectal cancer or adenomas will be accrued for this study. A total of 20 additional patients with no elevated risk of colorectal neoplasia will be accrued, but not randomized, for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I Sulindac
Oral sulindac twice daily.
Sulindac
Patients receive oral sulindac twice daily for 12 months.
Arm II Aspirin
Oral aspirin once daily.
Acetylsalicylic acid (Aspirin)
Patients receive oral aspirin once daily for 12 months.
Arm III Ursodiol
Oral ursodiol three times daily.
Ursodiol
Patients receive oral ursodiol three times daily for 12 months.
Arm IV: Sulindac Placebo
Oral sulindac placebo twice daily.
Sulindac Placebo
Oral sulindac placebo twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetylsalicylic acid (Aspirin)
Patients receive oral aspirin once daily for 12 months.
Sulindac
Patients receive oral sulindac twice daily for 12 months.
Ursodiol
Patients receive oral ursodiol three times daily for 12 months.
Sulindac Placebo
Oral sulindac placebo twice daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. with \>5 colorectal ACF and a prior history of colorectal cancer defined as Dukes A/B1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection (86 subjects)
3. with \>5 colorectal ACF and recent/current history of colorectal adenoma(s) defined as one of the following: one adenomatous polyp \>1cm or two or more adenomatous polyps of any size or one adenomatous polyp of any size and a documented history of adenomatous polyp(s) (86 subjects)
4. No elevated risk of colorectal cancer or adenomas (20 subjects)
5. Subjects will be permitted to use Nasonex but all other nasal steroids are prohibited. Subjects may change to Nasonex but must have discontinued previous nasal steroid use for at least 30 days prior to study randomization.
6. If participant is female and of childbearing potential, she must agree to use adequate contraception and must have a negative serum pregnancy test within 14 days prior to study drug administration
7. No use of investigational agent(s) within the last 3 months or at the discretion of the medical monitor
8. The subject will be allowed to proceed to randomization so long as all of the following laboratory criteria are met on baseline evaluation: Hgb \> 10.0 g/dl, platelet count \> 100,000/ul; WBC \> 3,000/ul; ALT \< 2 x upper limit of normal; AST \< 2 x upper limit of normal, and total bilirubin \<1.5mg/100ml.
9. Patients requiring use of hormone modulators such as Tamoxifen or Arimidex will be permitted to enroll providing they meet all of the eligibility criteria noted above
Exclusion Criteria
2. History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs , salicylates, or ursodeoxycholic acid
3. Use of NSAIDs, including aspirin, at any dose during the six months prior to study entry will require a three month washout period prior to eligibility beginning with the time of the last dose. Participants must be off all NSAIDs for three months prior to study entry. Individuals on cardioprotectant aspirin at any dose will not be eligible.
4. History of gastroduodenal ulcers documented endoscopically would preclude a patient from participation in the trial
5. Known inability to participate in the scheduled follow-up tests.
6. Significant medical or psychiatric problems which would make the patient a poor protocol candidate, in the opinion of the principal investigator.
7. "Unacceptable clinical risk" to proceed (based upon the subclinical discoveries made via baseline colonoscopy and biopsies).
8. Patient has undergone a total colectomy
9. Patient has received chemotherapy within the past 6 months of randomization into study. Topical chemotherapy will be assessed on a case-by-case basis. Any history of pelvic or rectal radiation therapy will exclude a patient from participating.
10. History of invasive carcinoma in the past five years (except patients with Dukes A/B1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection)
11. Patients with rectal cancer are excluded except for transanal excision without radiation.
12. Patients with acute liver disease, unexplained transaminase elevations or a history of renal stones would be excluded.
13. Participants will not be permitted to be randomized into the trial if any of the following laboratory values are reported at baseline : Hgb \< 10.0 g/dl, platelet count \<100,000/ul; WBC \< 3,000/ul; ALT \> 2 x upper limit of normal; AST \> 2 x upper limit of normal, and total bilirubin \>1.5mg/100ml.
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert S. Bresalier, MD
Role: STUDY_CHAIR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
UT MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDA-ID-01454
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000304433
Identifier Type: REGISTRY
Identifier Source: secondary_id
ID01-454
Identifier Type: -
Identifier Source: org_study_id